List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 142 studies with search of: Niacin OR "Nicotinic Acid" OR Nicotinamide
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)(COMPLETED)
Conditions: Hypercholesterolemia;   Hyperlipidemia
Interventions: Drug: Vytorin + Niaspan;   Drug: Vytorin;   Drug: Niaspan
2 Completed
Has Results 		To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: ezetimibe/simvastatin + niacin (ER);   Drug: Comparator: Placebo to ezetimibe/simvastatin;   Drug: Comparator: niacin (ER) tablet;   Drug: Comparator: ezetimibe (+) simvastatin;   Drug: Comparator: Placebo to Niacin (ER);   Drug: Comparator: ezetimibe/simvastatin and niacin (ER);   Drug: Comparator: ezetimibe and simvastatin;   Drug: Comparator: Placebo to niacin (ER)
3 Recruiting The Role of Dyslipidemia and Extended-Release Niacin in Stroke Recovery
Condition: Ischemic Stroke
Interventions: Drug: Extended-Release Niacin;   Drug: Placebo
4 Active, not recruiting Evaluation of the Effect of NICOtinic Acid (Niacin) on Elevated Lipoprotein(a) Levels (NICOLa Study)
Condition: Elevated Lipoprotein(a) Levels
Interventions: Drug: Nicotinic acid (niacin);   Drug: Placebo
5 Completed
Has Results 		A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol
Condition: Hypercholesterolemia
Interventions: Drug: Comparator: niacin + laropiprant;   Drug: Comparator: niacin;   Drug: Comparator: laropiprant;   Drug: Comparator: placebo
6 Recruiting The Genetics of Evoked Responses to Niacin and Endotoxemia: The GENE Study
Condition: Healthy Volunteers
Intervention: Drug: Immediate Release Niacin, Extended Release Niacin, Endotoxin
7 Recruiting Role of Prostaglandins on Niacin-Induced Flushing
Condition: Flushing
Intervention: Drug: Niacin and aspirin
8 Completed Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Condition: Opioid Abuse
Interventions: Drug: Niacin;   Drug: Oxycodone HCL plus Niacin;   Drug: Placebo;   Drug: Oxycodone HCl
9 Active, not recruiting Niacin, N-3 Fatty Acids and Insulin Resistance
Conditions: Metabolic Syndrome;   Hypertriglyceridemia
Interventions: Drug: omega-3 acid ethyl esters;   Drug: extended release niacin;   Drug: placebo;   Drug: combined treatment
10 Active, not recruiting Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)
Conditions: Coronary Disease;   Hypolipoproteinemia
Interventions: Behavioral: physical exercise;   Drug: niaspan (extended-release niacin);   Drug: niacin;   Other: control
11 Completed
Has Results 		A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Comparator: ER niacin (+) laropiprant;   Drug: Comparator: ER niacin;   Drug: Comparator: laropiprant;   Drug: Comparator: placebo
12 Not yet recruiting Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients
Conditions: Chronic Renal Failure;   Hemodialysis
Interventions: Drug: nicotinamide;   Drug: sevelamer;   Drug: cinacalcet
13 Completed
Has Results 		Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
Condition: Dyslipidemia
Interventions: Drug: Niacin extended-release (NER);   Drug: Niacin extended-release (NER) placebo;   Drug: Aspirin (ASA);   Drug: Aspirin (ASA) placebo
14 Recruiting Niacin and Endothelial Function in Early CKD
Condition: Chronic Kidney Disease
Interventions: Drug: Niacin;   Drug: Active Placebo
15 Active, not recruiting Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Condition: Peripheral Arterial Disease
Interventions: Drug: Ezetimibe;   Drug: Niaspan;   Drug: Statin therapy;   Behavioral: Standard care;   Drug: Aspirin;   Drug: Clopidogrel;   Drug: Placebo Niaspan;   Drug: Placebo Ezetimibe;   Procedure: Percutaneous transluminal angioplasty (PTA)
16 Completed SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia
Condition: Dyslipidemia
Intervention: Drug: Slo-Niacin, atorvastatin
17 Completed
Has Results 		Extended Niacin/Laropiprant in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus Type 2
Interventions: Drug: ER niacin/laropiprant;   Drug: Comparator : placebo (unspecified)
18 Active, not recruiting Retrospective Study of the Effectiveness and Safety of Niacin and Steroid Eye Drops for Retinal Vein Occlusions
Conditions: Central Retinal Vein Occlusion;   Branch Retinal Vein Occlusion
Intervention: Drug: nicotinic acid
19 Completed A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers
Condition: Healthy Subjects
Intervention: Drug: GSK256073A tablets + IR niacin tablets
20 Recruiting A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant (MK0524A)) in Patients With Dyslipidemia
Condition: Dyslipidemia
Interventions: Drug: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: Extended-release niacin (ERN);   Drug: Comparator: Placebo to ERN/LRPT

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services